Zermati et al. have suggested that Apaf-1 deficiency contributes to tumor progression not only by decreasing activation of the apoptotic caspase but also by reducing DNA damage-induced cell cycle arrest, thus weakening the cytostatic effects of chemotherapy and radiotherapy [31]. Here, APAF1 is linked to neoplasm.